Rallybio Corporation Common Stock (RLYB) is a publicly traded Healthcare sector company. As of October 26, 2026, RLYB trades at $16.74 with a market cap of $88.40M and a P/E ratio of 3.36. RLYB moved +0.00% today. Year to date, RLYB is +194.25%; over the trailing twelve months it is +241.19%. Its 52-week range spans $1.76 to $17.57. Rallies surfaces RLYB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallybio announces annual stockholder meeting: Rallybio will hold its annual stockholder meeting on November 4, 2026, to vote on its merger with Avenzo Therapeutics and a special cash distribution estimated at $82.7 million, or $13.56 per share. The merger is expected to close around November 6, subject to shareholder approval and other closing conditions.
| Metric | Value |
|---|---|
| Price | $16.74 |
| Market Cap | $88.40M |
| P/E Ratio | 3.36 |
| EPS | $5.05 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.57 |
| 52-Week Low | $1.76 |
| Volume | 3.60K |
| Avg Volume | 0 |
| Revenue (TTM) | $646.00K |
| Net Income | $45.55M |
| Gross Margin | 0.00% |
RLYB analyst coverage data. Average price target: $0.00.